Literature DB >> 23378123

Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.

Matthew E Levison1, Donald Kaye.   

Abstract

Complicated urinary tract infection is a challenging infection, since cure is difficult and either persistence or recurrence is common. The challenge is frequently increased because complicated urinary tract infection is often caused by gram-negative bacilli resistant to multiple antimicrobial drugs. In this review, we approach the therapy of complicated urinary tract infection with an emphasis on those caused by antimicrobial drug-resistant gram-negative uropathogens.

Entities:  

Year:  2013        PMID： 23378123     DOI： 10.1007/s11908-013-0315-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  38 in total

1.  Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial.

Authors:  Jutta Bleidorn; Ildikó Gágyor; Michael M Kochen; Karl Wegscheider; Eva Hummers-Pradier
Journal:  BMC Med       Date:  2010-05-26       Impact factor: 8.775

Review 2.  Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.

Authors:  Ann Pallett; Kieran Hand
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

4.  Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.

Authors:  Seung Soon Lee; Youngsu Kim; Doo Ryeon Chung
Journal:  J Infect       Date:  2010-11-03       Impact factor: 6.072

5.  Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high.

Authors:  Jae Hyun Jeon; Kyuseok Kim; Woong Dae Han; Sang Hoon Song; Kyoung Un Park; Joong Eui Rhee; Kyoung-Ho Song; Wan Beom Park; Eu Suk Kim; Sang Won Park; Nam Joong Kim; Myoung-Don Oh; Hong Bin Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 6.  Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; Antonios G Togias; Maria Karadima; Anastasios M Kapaskelis; Petros I Rafailidis; Stavros Athanasiou
Journal:  J Antimicrob Chemother       Date:  2010-06-29       Impact factor: 5.790

7.  Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-06-22       Impact factor: 17.586

8.  Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.

Authors:  C C Johnson; L Livornese; M J Gold; P G Pitsakis; S Taylor; M E Levison
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

9.  Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  J Antimicrob Chemother       Date:  2004-03-24       Impact factor: 5.790

10.  Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-03-20       Impact factor: 17.586
View more
  21 in total

1.  Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections.

Authors:  Ansal Shah; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Immunity to uropathogens: the emerging roles of inflammasomes.

Authors:  Claire Hamilton; Lionel Tan; Thomas Miethke; Paras K Anand
Journal:  Nat Rev Urol       Date:  2017-03-07       Impact factor: 14.432

Review 3.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

4.  Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study.

Authors:  Adi Turjeman; Tanya Babich; Miquel Pujol; Jordi Carratalà; Evelyn Shaw; Aina Gomila-Grange; Cuong Vuong; Ibironke Addy; Irith Wiegand; Sally Grier; Alasdair MacGowan; Christiane Vank; Nienke Cuperus; Leo van den Heuvel; Leonard Leibovici; Noa Eliakim-Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-02       Impact factor: 3.267

Review 5.  Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection.

Authors:  Ana Flores-Mireles; Teri N Hreha; David A Hunstad
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

6.  Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

Authors:  Keith S Kaye; Tanaya Bhowmick; Symeon Metallidis; Susan C Bleasdale; Olexiy S Sagan; Viktor Stus; Jose Vazquez; Valerii Zaitsev; Mohamed Bidair; Erik Chorvat; Petru Octavian Dragoescu; Elena Fedosiuk; Juan P Horcajada; Claudia Murta; Yaroslav Sarychev; Ventsislav Stoev; Elizabeth Morgan; Karen Fusaro; David Griffith; Olga Lomovskaya; Elizabeth L Alexander; Jeffery Loutit; Michael N Dudley; Evangelos J Giamarellos-Bourboulis
Journal:  JAMA       Date:  2018-02-27       Impact factor: 56.272

Review 7.  Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review.

Authors:  Mandana Izadpanah; Hossein Khalili
Journal:  J Res Pharm Pract       Date:  2015 Jul-Sep

8.  Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING).

Authors:  Evelyn Shaw; Ibironke Addy; Margaret Stoddart; Christiane Vank; Sally Grier; Irith Wiegand; Leonard Leibovici; Noa Eliakim-Raz; Laura Vallejo-Torres; Stephen Morris; Alasdair MacGowan; Jordi Carratalà; Miquel Pujol
Journal:  BMJ Open       Date:  2016-07-29       Impact factor: 2.692

Review 9.  Adhesive Pili in UTI Pathogenesis and Drug Development.

Authors:  Caitlin N Spaulding; Scott J Hultgren
Journal:  Pathogens       Date:  2016-03-15

10.  Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Authors:  Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.